Stifel Nicolaus Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its price objective lowered by equities research analysts at Stifel Nicolaus from $105.00 to $95.00 in a research note issued on Monday,MarketScreener reports. The brokerage presently has a “hold” rating on the medical technology company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 9.96% from the company’s previous close.

Several other research analysts have also recently weighed in on MDT. Citigroup dropped their price objective on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday. Sanford C. Bernstein boosted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Needham & Company LLC restated a “buy” rating and issued a $120.00 price objective on shares of Medtronic in a research report on Thursday, March 26th. Wells Fargo & Company assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective for the company. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $109.10.

Medtronic Stock Performance

MDT stock opened at $86.40 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The company has a 50 day moving average price of $93.90 and a 200 day moving average price of $96.13. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The stock has a market capitalization of $110.92 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the previous year, the company posted $1.38 EPS. Medtronic’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic will post 5.46 EPS for the current year.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Several institutional investors and hedge funds have recently made changes to their positions in MDT. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic in the 3rd quarter valued at $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic in the 4th quarter valued at $27,000. Anfield Capital Management LLC grew its holdings in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the period. Finally, Monetary Solutions Ltd acquired a new position in shares of Medtronic in the 4th quarter valued at $27,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Citi trimmed its price target to $110 but maintained a Buy rating, signaling continued analyst conviction and meaningful upside vs. current levels. Citigroup Raises/Remains Positive on MDT
• Positive Sentiment: Evercore lowered its target to $108 but kept an Outperform rating, also implying multi‑ten‑percent upside and signaling confidence in MDT’s medium‑term fundamentals. Evercore Adjusts MDT PT
• Positive Sentiment: Argus reduced its target to $115 but retained a Buy rating, another vote of confidence that leaves sizable upside from current levels. Argus Maintains Buy on MDT
• Positive Sentiment: Market research projects steady long‑term growth (5.9% CAGR) in the global lung cancer surgery market — a tailwind for device makers like Medtronic that supply minimally invasive and robotic-assisted tools. This supports longer‑term revenue growth outlooks. Lung Cancer Surgery Market Growth
• Neutral Sentiment: Merit Medical’s acquisition of View Point Medical is industry M&A activity but not directly material to Medtronic’s near-term outlook. Merit Medical Acquisition
• Neutral Sentiment: Inogen’s board appointment is unrelated to Medtronic’s business and unlikely to move MDT stock. Inogen Board Appointment
• Negative Sentiment: Stifel cut its price target to $95 and reiterated a Hold, explicitly citing dilution/transaction impacts from the MiniMed/diabetes spin-off and a MiniMed IPO as limiting near‑term upside — a clear near‑term headwind for sentiment. Stifel Lowers MDT Target, Cites MiniMed IPO Effects
• Negative Sentiment: Johnson & Johnson launched a CE‑marked Varipulse Pro pulsed field ablation platform in Europe — increased competition in electrophysiology/ablation could pressure share gains or pricing in those product lines. J&J Varipulse Pro Launch

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).